Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.6800 (-6.34%) ($7.6300 - $8.3800) on Thu. Dec. 5, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.78% (three month average) | RSI | 45 | Latest Price | $7.6800(-6.34%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.4% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(59%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -1.89% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-7%) TLT(-7%) IGOV(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.89% (StdDev 3.78%) | Hourly BBV | 0 () | Intraday Trend | -7.4% | | | |
|
Resistance Level | $7.85 | 5 Day Moving Average | $7.94(-3.27%) | 10 Day Moving Average | $7.81(-1.66%) | 20 Day Moving Average | $7.85(-2.17%) | To recent high | -6.3% | To recent low | 50.6% | Market Cap | $973m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |